Bioanalytical Testing Services Market (By Test Type: Pharmacokinetic, Pharmacodynamics, Bioavailability, Bioequivalence; By Molecules: Small Molecules, Large Molecules; By Application: Cardiology, Gastroenterology, Neurology, Oncology, Others; By End User: Pharmaceutical and Biopharmaceutical Companies, Contract Development and Manufacturing Organizations, Contract Research Organizations) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2034
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Bioanalytical Testing Services Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Bioanalytical Testing Services Market, by Test Type, 2024-2034
8.1.1. Pharmacokinetic
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Pharmacodynamics
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Bioavailability
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Bioequivalence
8.1.4.1. Market Revenue and Forecast (2021-2034)
9.1. Bioanalytical Testing Services Market, by Molecules, 2024-2034
9.1.1. Small Molecules
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Large Molecules
9.1.2.1. Market Revenue and Forecast (2021-2034)
10.1. Bioanalytical Testing Services Market, by Application, 2024-2034
10.1.1. Cardiology
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Gastroenterology
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Neurology
10.1.3.1. Market Revenue and Forecast (2021-2034)
10.1.4. Oncology
10.1.4.1. Market Revenue and Forecast (2021-2034)
10.1.5. Others
10.1.5.1. Market Revenue and Forecast (2021-2034)
11.1. Bioanalytical Testing Services Market, by End User, 2024-2034
11.1.1. Pharmaceutical and Biopharmaceutical Companies
11.1.1.1. Market Revenue and Forecast (2021-2034)
11.1.2. Contract Development and Manufacturing Organizations
11.1.2.1. Market Revenue and Forecast (2021-2034)
11.1.3. Contract Research Organizations
11.1.3.1. Market Revenue and Forecast (2021-2034)
12.1. North America
12.1.1. Market Revenue and Forecast, by Test Type (2021-2034)
12.1.2. Market Revenue and Forecast, by Molecules (2021-2034)
12.1.3. Market Revenue and Forecast, by Application (2021-2034)
12.1.4. Market Revenue and Forecast, by End User (2021-2034)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Test Type (2021-2034)
12.1.5.2. Market Revenue and Forecast, by Molecules (2021-2034)
12.1.5.3. Market Revenue and Forecast, by Application (2021-2034)
12.1.5.4. Market Revenue and Forecast, by End User (2021-2034)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Test Type (2021-2034)
12.1.6.2. Market Revenue and Forecast, by Molecules (2021-2034)
12.1.6.3. Market Revenue and Forecast, by Application (2021-2034)
12.1.6.4. Market Revenue and Forecast, by End User (2021-2034)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Test Type (2021-2034)
12.2.2. Market Revenue and Forecast, by Molecules (2021-2034)
12.2.3. Market Revenue and Forecast, by Application (2021-2034)
12.2.4. Market Revenue and Forecast, by End User (2021-2034)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Test Type (2021-2034)
12.2.5.2. Market Revenue and Forecast, by Molecules (2021-2034)
12.2.5.3. Market Revenue and Forecast, by Application (2021-2034)
12.2.5.4. Market Revenue and Forecast, by End User (2021-2034)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Test Type (2021-2034)
12.2.6.2. Market Revenue and Forecast, by Molecules (2021-2034)
12.2.6.3. Market Revenue and Forecast, by Application (2021-2034)
12.2.6.4. Market Revenue and Forecast, by End User (2021-2034)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Test Type (2021-2034)
12.2.7.2. Market Revenue and Forecast, by Molecules (2021-2034)
12.2.7.3. Market Revenue and Forecast, by Application (2021-2034)
12.2.7.4. Market Revenue and Forecast, by End User (2021-2034)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Test Type (2021-2034)
12.2.8.2. Market Revenue and Forecast, by Molecules (2021-2034)
12.2.8.3. Market Revenue and Forecast, by Application (2021-2034)
12.2.8.4. Market Revenue and Forecast, by End User (2021-2034)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Test Type (2021-2034)
12.3.2. Market Revenue and Forecast, by Molecules (2021-2034)
12.3.3. Market Revenue and Forecast, by Application (2021-2034)
12.3.4. Market Revenue and Forecast, by End User (2021-2034)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Test Type (2021-2034)
12.3.5.2. Market Revenue and Forecast, by Molecules (2021-2034)
12.3.5.3. Market Revenue and Forecast, by Application (2021-2034)
12.3.5.4. Market Revenue and Forecast, by End User (2021-2034)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Test Type (2021-2034)
12.3.6.2. Market Revenue and Forecast, by Molecules (2021-2034)
12.3.6.3. Market Revenue and Forecast, by Application (2021-2034)
12.3.6.4. Market Revenue and Forecast, by End User (2021-2034)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Test Type (2021-2034)
12.3.7.2. Market Revenue and Forecast, by Molecules (2021-2034)
12.3.7.3. Market Revenue and Forecast, by Application (2021-2034)
12.3.7.4. Market Revenue and Forecast, by End User (2021-2034)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Test Type (2021-2034)
12.3.8.2. Market Revenue and Forecast, by Molecules (2021-2034)
12.3.8.3. Market Revenue and Forecast, by Application (2021-2034)
12.3.8.4. Market Revenue and Forecast, by End User (2021-2034)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Test Type (2021-2034)
12.4.2. Market Revenue and Forecast, by Molecules (2021-2034)
12.4.3. Market Revenue and Forecast, by Application (2021-2034)
12.4.4. Market Revenue and Forecast, by End User (2021-2034)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Test Type (2021-2034)
12.4.5.2. Market Revenue and Forecast, by Molecules (2021-2034)
12.4.5.3. Market Revenue and Forecast, by Application (2021-2034)
12.4.5.4. Market Revenue and Forecast, by End User (2021-2034)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Test Type (2021-2034)
12.4.6.2. Market Revenue and Forecast, by Molecules (2021-2034)
12.4.6.3. Market Revenue and Forecast, by Application (2021-2034)
12.4.6.4. Market Revenue and Forecast, by End User (2021-2034)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Test Type (2021-2034)
12.4.7.2. Market Revenue and Forecast, by Molecules (2021-2034)
12.4.7.3. Market Revenue and Forecast, by Application (2021-2034)
12.4.7.4. Market Revenue and Forecast, by End User (2021-2034)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Test Type (2021-2034)
12.4.8.2. Market Revenue and Forecast, by Molecules (2021-2034)
12.4.8.3. Market Revenue and Forecast, by Application (2021-2034)
12.4.8.4. Market Revenue and Forecast, by End User (2021-2034)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Test Type (2021-2034)
12.5.2. Market Revenue and Forecast, by Molecules (2021-2034)
12.5.3. Market Revenue and Forecast, by Application (2021-2034)
12.5.4. Market Revenue and Forecast, by End User (2021-2034)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Test Type (2021-2034)
12.5.5.2. Market Revenue and Forecast, by Molecules (2021-2034)
12.5.5.3. Market Revenue and Forecast, by Application (2021-2034)
12.5.5.4. Market Revenue and Forecast, by End User (2021-2034)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Test Type (2021-2034)
12.5.6.2. Market Revenue and Forecast, by Molecules (2021-2034)
12.5.6.3. Market Revenue and Forecast, by Application (2021-2034)
12.5.6.4. Market Revenue and Forecast, by End User (2021-2034)
13.1. PPD, Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. ICON Plc
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Charles River Laboratories International
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Covance, Inc.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. IQVIA
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Syneos Health
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. SGS SA
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Toxikon
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Intertek Group Plc
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Pace Analytical Services LLC
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample